Cover Image

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis proc...

Full description

Saved in:
Bibliographic Details
Main Authors: Lee, Han-Chung, Hamzah, Hamizun, Leong, Melody Pui-Yee, Yusof, Hadri Md, Habib, Omar, Abidin, Shahidee Zainal, Seth, Eryse Amira, Lim, Siong-Meng, Vidyadaran, Sharmili, Moklas, Mohamad Aris Mohd, Abdullah, Maizaton Atmadini, Nordin, Norshariza, Hassan, Zurina, Cheah, Pike-See, Ling, King-Hwa
Format: Article
Published: Nature Research 2021
Subjects:
QL Zoology
R Medicine
R Medicine (General)
Online Access:http://eprints.um.edu.my/34626/
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://eprints.um.edu.my/34626/

Similar Items